Mallinckrodt Medical, Inc.

Mallinckrodt, Inc.

Mary Marmion Dyszlewski

Edward A Deutsch

Joseph E Bugaj

Mark A DeRosch

William L Neumann

Ananthachari Srinivasan

Dennis L Nosco

Steven R Woulfe

Roger Alberto

James W Brodack

Jack L Erion

Mark A Derosch

The invention relates to novel aminocarboxylate ligands that are suitable for complexing with a radionuclide, and are useful as imaging agents for diagnostic purposes. In accordance with the present invention, a method of preparing a compound of formula (I): fac-[M(CO)(OH)], wherein M is Mn,Tc,Re orRe, involves reacting a metal in permetallate form with carbon monoxide and a reducing agent, wherein a mixture of a basic borate buffer and a reducing agent soluble in water but not substantially decomposed by water is solved in a water containing solvent system containing a solution of the metal in permanganate, pertechnetate or perrhenate form in the presence of carbon monoxide. The compound of formula (I) can be reacted with a ligand Lto form a compound of formula (II): fac-[M(CO)(X)L], wherein M is as defined above Lis a multidentate ligand, and n is a charge of the ligand Lincreased with one + charge. The invention also is directed to novel compounds, and kits for carrying out the disclosed methods.

Group (VII) transition-metal complexes with multidentate aminopolycarboxylate ligands and a kit for producing them

The present invention relates to the stabilization of radiopharmaceutical preparations and to the stabilization of components of radiopharmaceutical kits. In particular, the present invention relates to stabilization of lyophilized components of radiopharmaceutical kits by the addition of a cyclic oligosaccharide, such as, a modified or unmodified cyclodextrin, to the kit.

Stabilized radiopharmaceutical kits

This invention relates to radiolabeled peptide compositions for radiopharmaceutical use and, more specifically, to radiolabeled peptides for diagnostic or therapeutic use having an unmodified carboxy terminal amino acid. The radiopharmaceutical composition may be used for targeting a selected biological site. The radiolabeled peptide is characterized by having its carboxy terminal amino acid in its carboxylic acid form and the peptide is coupled to a diagnostic or therapeutic radionuclide by a chelating agent. The radiopharmaceutical composition preferably comprises a radiolabeled peptide selected from the group consisting of somatostatin, an analog of somatostatin, a derivative of somatostatin and peptides capable of binding to the somatostatin receptor, where the peptide is coupled to a diagnostic or therapeutic radionuclide by a chelating agent has its carboxy terminal amino acid in its carboxylic acid form.

Radiolabeled peptide compositions for site-specific targeting

Peptide compositions and method of radiolabeling

The present invention relates to novel radiopharmaceutical imaging agents having non-stannous reductants. The present invention further relates to kits for forming radiopharmaceutical imaging agents, such kits including non-stannous reducing agents.

Radiopharmaceutical formulations having non-stannous reductants

A myocardial imaging agent for use in humans comprising a Tc(III) complex ligated in a planar position by a tetradentate ligand having incorporated therein four hard atoms and two furanone rings and in the axial positions by phosphines containing dioxanyl or ether moieties. The agent exhibits improved biodistribution, improved labeling and extremely rapid blood clearance following administration to a human. The agent has high myocardial uptake accompanied with exceptionally rapid hepatobilary clearance and extensive renal clearance to give sufficiently high heart/liver and heart/lung ratio that provide nearly ideal myocardial images in humans.

99MTC(III) myocardial imaging agents and method of use

A myocardial imaging agent for use in humans comprising a Tc(III) complex ligated in a planar position by a tetradentate ligand having incorporated therein four hard atotms and two furanone rings and in the axial positions by phosphines containing dioxanyl or ether moieties. The agent exhibits improved biodistribution, improved labeling and extremely rapid blood clearance following administration to a human. The agent has high myocardial uptake accompanied with exceptionally rapid hepatobilary clearance and extensive renal clearance to give sufficiently high heart/liver and heart/lung ratio that provide nearly ideal myocardial images in humans. A kit for producing the myocardial imaging agent is provided.

Growing community of inventors

Maryland Heights, MO, United States of America

Mary Marmion Dyszlewski